Is 2179.HK overvalued or undervalued?

2179.HK currently has a P/E ratio of -4.89. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Jiangsu Recbio Technology Co., Ltd. stock?

Jiangsu Recbio Technology Co., Ltd. trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2179.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2179.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2179.HK to protect their purchasing power. Because 2179.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2179.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2179.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2179.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2179.HK

Jiangsu Recbio Technology Co., Ltd.

HK$4.42+HK$0.01+0.11%

HKSE / HKD

Market cap

HK$2.3B

P/E

-4.9

EPS (TTM)

HK$-0.11

Dividend yield

0.00%

Beta

0.08

1Y return

-35.94%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$975,5992021

$771,6462022

$4M2023

$4M2024

$2M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity1.35Moderate
Current ratio0.53
Cash ratio0.24
Net margin-5,134.3%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2179.HK-4.9
Healthcare sector median26.8
S&P 50022.0

Trades about 118% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.09
Price to book4.66
EPS (TTM)HK$-0.11
Payout ratio0%
FCF yield-31.51%

Range & risk

HK$3.40HK$7.20

Trading in the lower third of its 52-week band

Beta0.08

Profile

What Jiangsu Recbio Technology Co., Ltd. actually does

Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.

CEO

Yong Liu

Employees

491

Headquarters

Taizhou, JS

Founded

2022-03-31

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2179.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2179.HK has a beta of 0.08, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Jiangsu Recbio Technology Co., Ltd.